American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
13 09 2022
13 09 2022
Historique:
received:
14
03
2022
accepted:
18
04
2022
pubmed:
4
5
2022
medline:
1
9
2022
entrez:
3
5
2022
Statut:
ppublish
Résumé
COVID-19-related acute illness is associated with an increased risk of venous thromboembolism (VTE). These evidence-based guidelines from the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation in patients with COVID-19. ASH formed a multidisciplinary guideline panel that included patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process and performed systematic evidence reviews (through November 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 as part of the living phase of these guidelines. The panel made one additional recommendation. The panel issued a conditional recommendation in favor of therapeutic-intensity over prophylactic-intensity anticoagulation in patients with COVID-19-related acute illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of risk of thrombosis and bleeding. The panel also noted that heparin (unfractionated or low molecular weight) may be preferred because of a preponderance of evidence with this class of anticoagulants. This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation in patients with COVID-19-related acute illness.
Sections du résumé
BACKGROUND
COVID-19-related acute illness is associated with an increased risk of venous thromboembolism (VTE).
OBJECTIVE
These evidence-based guidelines from the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation in patients with COVID-19.
METHODS
ASH formed a multidisciplinary guideline panel that included patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University GRADE Centre supported the guideline development process and performed systematic evidence reviews (through November 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 as part of the living phase of these guidelines.
RESULTS
The panel made one additional recommendation. The panel issued a conditional recommendation in favor of therapeutic-intensity over prophylactic-intensity anticoagulation in patients with COVID-19-related acute illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of risk of thrombosis and bleeding. The panel also noted that heparin (unfractionated or low molecular weight) may be preferred because of a preponderance of evidence with this class of anticoagulants.
CONCLUSION
This conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation in patients with COVID-19-related acute illness.
Identifiants
pubmed: 35503027
pii: 485124
doi: 10.1182/bloodadvances.2022007561
pmc: PMC9068240
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4915-4923Subventions
Organisme : NHLBI NIH HHS
ID : K01 HL135466
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Infect Dis Ther. 2021 Dec;10(4):1837-1885
pubmed: 34328629
BMJ. 2016 Jun 28;353:i2016
pubmed: 27353417
BMC Health Serv Res. 2004 Dec 22;4(1):38
pubmed: 15615589
N Engl J Med. 2021 Aug 26;385(9):790-802
pubmed: 34351721
Clin Pharmacol Ther. 2022 Mar;111(3):614-623
pubmed: 34862791
Thromb Haemost. 2022 Feb;122(2):295-299
pubmed: 34638151
BMJ. 2021 Oct 14;375:n2400
pubmed: 34649864
Blood Adv. 2021 Feb 9;5(3):872-888
pubmed: 33560401
Res Pract Thromb Haemost. 2021 Feb 24;5(2):296-300
pubmed: 33733028
Ann Intern Med. 2012 Apr 3;156(7):525-31
pubmed: 22473437
Eur Heart J Cardiovasc Pharmacother. 2021 Sep 14;:
pubmed: 34519777
Acute Med Surg. 2021 Nov 16;8(1):e706
pubmed: 34815889
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620
pubmed: 34617959
J Infect Chemother. 2022 Feb;28(2):257-265
pubmed: 34840039
Lancet. 2021 Jun 12;397(10291):2253-2263
pubmed: 34097856
Res Pract Thromb Haemost. 2020 Oct 13;4(7):1178-1191
pubmed: 33043231
Blood Adv. 2021 Oct 26;5(20):3951-3959
pubmed: 34474482
J Clin Epidemiol. 2017 Jan;81:101-110
pubmed: 27713072
Prev Med Rep. 2019 Jan 15;13:268-269
pubmed: 30723661
Eur Respir J. 2021 Apr 15;57(4):
pubmed: 33692120
J Clin Epidemiol. 2011 Apr;64(4):395-400
pubmed: 21194891
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
CMAJ. 2003 Sep 30;169(7):677-80
pubmed: 14517128
Ann Intern Med. 2015 Oct 6;163(7):548-53
pubmed: 26436619
Anaesth Crit Care Pain Med. 2021 Aug;40(4):100919
pubmed: 34182166
Res Pract Thromb Haemost. 2021 Dec 17;5(8):e12638
pubmed: 34977448
BMJ. 2016 Jun 30;353:i2089
pubmed: 27365494
Chest. 2021 Mar;159(3):1182-1196
pubmed: 33217420
Blood Adv. 2020 May 12;4(9):2095-2110
pubmed: 32396622
CMAJ. 2020 Aug 10;192(32):E901-E906
pubmed: 32778601